111 related articles for article (PubMed ID: 37587851)
1. Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
Sather CL; Yang P; Zhang C; Fitzgibbon MP; Fournier M; Toloza E; Tandon A; Schabath M; Yoder S; Nair VS
Cancer Med; 2023 Sep; 12(17):17632-17637. PubMed ID: 37587851
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.
Nair VS; Hui AB; Chabon JJ; Esfahani MS; Stehr H; Nabet BY; Zhou L; Chaudhuri AA; Benson J; Ayers K; Bedi H; Ramsey M; Van Wert R; Antic S; Lui N; Backhus L; Berry M; Sung AW; Massion PP; Shrager JB; Alizadeh AA; Diehn M
Cancer Res; 2022 Aug; 82(16):2838-2847. PubMed ID: 35748739
[TBL] [Abstract][Full Text] [Related]
3. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
[TBL] [Abstract][Full Text] [Related]
4. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
[TBL] [Abstract][Full Text] [Related]
5. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
[TBL] [Abstract][Full Text] [Related]
6. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels.
Jongbloed EM; Jansen MPHM; de Weerd V; Helmijr JA; Beaufort CM; Reinders MJT; van Marion R; van IJcken WFJ; Sonke GS; Konings IR; Jager A; Martens JWM; Wilting SM; Makrodimitris S
Sci Rep; 2023 Jun; 13(1):10424. PubMed ID: 37369746
[TBL] [Abstract][Full Text] [Related]
7. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
9. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
[TBL] [Abstract][Full Text] [Related]
10. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma.
Lasseter K; Nassar AH; Hamieh L; Berchuck JE; Nuzzo PV; Korthauer K; Shinagare AB; Ogorek B; McKay R; Thorner AR; Lee GM; Braun DA; Bhatt RS; Freedman M; Choueiri TK; Kwiatkowski DJ
Genet Med; 2020 Aug; 22(8):1366-1373. PubMed ID: 32341571
[TBL] [Abstract][Full Text] [Related]
12. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
13. Discrimination of Germline
Hu Y; Alden RS; Odegaard JI; Fairclough SR; Chen R; Heng J; Feeney N; Nagy RJ; Shah J; Ulrich B; Gutierrez M; Lanman RB; Garber JE; Paweletz CP; Oxnard GR
Clin Cancer Res; 2017 Dec; 23(23):7351-7359. PubMed ID: 28947568
[No Abstract] [Full Text] [Related]
14. Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples.
Werner TV; Kock S; Weber I; Kayser G; Werner M; Lassmann S
J Mol Diagn; 2022 Jul; 24(7):784-802. PubMed ID: 35787794
[TBL] [Abstract][Full Text] [Related]
15. Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.
Zhao X; Wang A; Walter V; Patel NM; Eberhard DA; Hayward MC; Salazar AH; Jo H; Soloway MG; Wilkerson MD; Parker JS; Yin X; Zhang G; Siegel MB; Rosson GB; Earp HS; Sharpless NE; Gulley ML; Weck KE; Hayes DN; Moschos SJ
PLoS One; 2015; 10(6):e0129280. PubMed ID: 26076459
[TBL] [Abstract][Full Text] [Related]
16. Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma.
Hirotsu Y; Otake S; Ohyama H; Amemiya K; Higuchi R; Oyama T; Mochizuki H; Goto T; Omata M
Sci Rep; 2020 Feb; 10(1):3391. PubMed ID: 32099048
[TBL] [Abstract][Full Text] [Related]
17. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
18. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients.
Rolfo C; Malapelle U; Russo A
Cancer Res; 2022 Aug; 82(16):2826-2828. PubMed ID: 35971678
[TBL] [Abstract][Full Text] [Related]
19. Bronchoalveolar Lavage as Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer.
Lin X; Cai Y; Zong C; Chen B; Shao D; Cui H; Li Z; Xu P
Technol Cancer Res Treat; 2023; 22():15330338231202881. PubMed ID: 37743841
[No Abstract] [Full Text] [Related]
20. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
